Research output per year
Research output per year
Search results
-
2021
Erratum: Angiokines Associated with Outcomes after Sunitinib or Everolimus Treatment in Patients with Non–Clear Cell Renal Cell Carcinoma (Clin Cancer Res (2021) 27 (3317–3328) DOI: 10.1158/1078-0432.CCR-20-4504)
Armstrong, A. J., Nixon, A. B., Carmack, A., Yang, Q., Eisen, T., Stadler, W. M., Jones, R. J., Garcia, J. A., Vaishampayan, U. N., Picus, J., Hawkins, R. E., Hainsworth, J. D., Kollmannsberger, C. K., Logan, T. F., Puzanov, I., Pickering, L. M., Ryan, C. W., Protheroe, A., George, D. J. & Halabi, S., Jun 2021, In: Clinical Cancer Research. 27, 12, p. 3503 1 p.Research output: Contribution to journal › Comment/debate
Open Access2 Scopus citations -
2018
Corrigendum to ‘Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update’ [Eur J Cancer 94 (May 2018) 115–125] (European Journal of Cancer (2018) 94 (115–125), (S0959804918301813) (10.1016/j.ejca.2018.02.012))
Choueiri, T. K., Hessel, C., Halabi, S., Sanford, B., Michaelson, M. D., Hahn, O., Walsh, M., Olencki, T., Picus, J., Small, E. J., Dakhil, S., Feldman, D. R., Mangeshkar, M., Scheffold, C., George, D. & Morris, M. J., Nov 2018, In: European Journal of Cancer. 103, p. 287 1 p.Research output: Contribution to journal › Comment/debate
Open Access5 Scopus citations